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Abstract
Background: Macrophage activation is involved in the pathogenesis of polymyositis (PM)/dermatomyositis (DM).
CD163, a scavenger receptor expressed on the surface of activated macrophages, mediates anti-inflammatory
functions. This study aimed to evaluate the clinical significance of soluble CD163 (sCD163) in PM/DM-related
interstitial lung disease (ILD).
Methods: The main subjects were 48 patients with PM/DM-related ILD. As controls, 10 patients with PM/DM
without ILD and 20 healthy volunteers were enrolled. In patients with PM/DM-related ILD, the baseline
characteristics and clinical course were obtained through a review of patient medical records. Serum sCD163 levels
at ILD diagnosis were quantified by enzyme-linked immunosorbent assay, which were compared with the other
baseline clinical factors and evaluated for potential as a prognostic biomarker. In addition, immunohistochemistry
analysis using anti-human CD163 antibody was performed on the lung sections of two patients with DM-related
ILD (a survivor and non-survivor, respectively) and one patient with early-stage lung cancer as a normal control.
Results: The median value of serum sCD163 in patients with PM/DM-related ILD was 818 ng/mL, which was
higher than that of PM/DM patients without ILD and healthy volunteers (716 ng/mL and 340 ng/mL, respectively).
Significant but mild correlations with serum sCD163 levels were observed for serum C-reactive protein levels
(r = 0.322) and % predicted forced vital capacity (r = −0.301) in patients with PM/DM-related ILD. A Cox proportional
hazard model demonstrated that patients with PM/DM-related ILD and higher sCD163 levels had worse prognosis
(age-adjusted and gender-adjusted hazard ratio per 100 ng/mL increase 1.27, 95% confidence interval 1.11–1.45,
P <0.001). In immunohistochemistry analysis, compared with normal lung, alveolar infiltration of CD163-positive
macrophages was evident in the lungs of patients with DM-related ILD. Especially, the finding was more severe in
the non-survivor’s lung.
Conclusions: Serum sCD163 might be a potential biomarker for predicting the severity and prognosis of PM/DM-
related ILD. Our results suggest the importance of macrophage activation in the disease.
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Background
Polymyositis (PM) and dermatomyositis (DM) are
systemic inflammatory diseases affecting the muscles,
skin, and several other organs including the lungs [1, 2].
Interstitial lung disease (ILD) is a common complication
seen in 20–78% of patients with PM/DM and can be a
prognostic determinant [3–8]. Particularly, patients with
DM and clinically amyopathic DM (CADM) frequently
develop an acute and severe form of ILD [4, 5]. Thus,
management of ILD is essential for the care of patients
with PM/DM, and appropriate biomarkers reflecting the
disease severity are required.
CD163, a scavenger receptor specifically expressed on
the surface of activated macrophages and monocytes, is
involved in the uptake of hemoglobin-haptoglobin and
mediates the clearance of hemoglobin [9]. CD163
expression is upregulated by several inflammatory cyto-
kines including interleukin (IL)-6 [10, 11]. Inflammatory
infiltrates containing CD163-positive macrophages are
frequently found in the diseased muscles in PM/DM [12,
13], where activated macrophages themselves directly
induce inflammation and also mediate inflammatory re-
sponses via lymphocyte activation [14, 15]. Indeed, PM/
DM is one of the diseases that occasionally cause macro-
phage activation syndrome (MAS). In contrast, macro-
phages could produce transforming growth factor-β, the
most prominent fibrosis-inducing molecule, in chronic
lung inflammation [16]. Additionally, activated macro-
phages expressing CD163 have been demonstrated to
play a key role during lung fibrosis [17]. Macrophage ac-
tivation would be involved in the pathogenesis of PM/
DM-related ILD.
Upon acute and chronic inflammations, CD163 is shed
from surface of activated macrophages and released into
peripheral blood in the soluble form [11]. Therefore, sol-
uble CD163 (sCD163) in the serum has been highlighted
as a representative of macrophage activation and as a
biomarker in several inflammatory diseases [18–23].
However, the clinical significance of this molecule in
PM/DM-related ILD is not fully understood. The aim of
this retrospective study was to evaluate the potential of
serum sCD163 as a biomarker in PM/DM-related ILD.
Methods
Patient selection
A retrospective review of 52 patients with PM/DM-re-
lated ILD, consecutively admitted to Hamamatsu Uni-
versity Hospital between 1995 and 2014, was conducted.
Subsequently, four patients (one with PM, one with
CADM, and two with classic DM) who received im-
munosuppressive treatment with corticosteroids on
diagnosis of ILD were excluded. Thus, this study in-
cluded the remaining 48 patients with PM/DM-related
ILD. Among them, 45 patients had never received
immunosuppressive treatment, whereas the other 3 pa-
tients had received treatment but terminated it at least
1 year before the ILD diagnosis. In addition, 10 patients
with PM/DM without ILD, who had not received im-
munosuppressive treatment, and 20 age-matched and
gender-matched healthy volunteers were enrolled as
control groups (Additional file 1: Table S1).
Classic PM/DM was diagnosed according to the cri-
teria of Bohan and Peter [2]. Patients with definite or
probable PM/DM according to these criteria were in-
cluded in the study. CADM was diagnosed when a pa-
tient had a skin rash typical of DM without clinical
evidence of myositis and with little or no increase in
serum creatine kinase (CK) [5, 24]. The diagnosis of
classic PM/DM and CADM had been confirmed by the
dermatologists and/or rheumatologists and the pulmo-
nologists in our institution. The diagnosis of ILD was
based on the radiological assessment of high-resolution
computed tomography (HRCT) of the chest, which in-
cluded appearances of bilateral reticulation, ground-glass
attenuation, or consolidation.
Data collection
The patients’ clinical data at the time of PM/DM-related
ILD diagnosis were obtained through medical record
reviews. These data included symptoms; laboratory
findings; pulmonary function test results (forced vital
capacity (FVC); diffusing capacity of the lung for carbon
monoxide (DLco), measured using a single breath tech-
nique); analyses of bronchoalveolar lavage (BAL) fluid;
treatment; and prognosis.
Serum sCD163 levels were quantified by enzyme-
linked immunosorbent assay in accordance with the
manufacturer's protocol (eBioscience, USA). The sam-
ples were obtained at the time of PM/DM-related ILD
diagnosis and stored at −80 °C for future analysis. All
measurements were done in duplicate and the mean
value of serum sCD163 was recorded. Written informed
consent for serum conservation was obtained from all
the subjects.
Immunohistochemical analysis
Lung specimens were obtained from two patients with
classic DM-related ILD (on surgical lung biopsy and
autopsy, respectively) and one patient with early-stage
lung cancer as a normal control (on lung resection).
These specimens had been fixed in 10% formalin and
embedded in paraffin. Deparaffinized sections (5 μm
thick) were preheated to 120 °C for 20 minutes. After
blocking endogenous peroxidase activity with 0.3% H2O2
for 20 minutes, the slides were incubated with the rabbit
anti-human CD163 monoclonal antibody (1:200; Leica
Biosystems, Germany) or isotype control antibody
(Jackson ImmunoResearch Laboratories, USA) for 1 h at
Enomoto et al. Arthritis Research & Therapy  (2017) 19:9 Page 2 of 9
20 °C. Subsequently, the sections were incubated with
biotin-conjugated gout anti-rabbit IgG antibody
(Nichirei, Japan) for 15 minutes, and the immunore-
action was visualized using a 3,3-diaminobenzidine
(DAB) chromogen solution (DAB substrate kit; Vector
Laboratories, USA), and then counterstained with
hematoxylin. Additionally, hematoxylin–eosin staining
was also done on another slide from each patient.
Statistical analysis
Data were described as numbers (percentages) or me-
dians with observed ranges. Spearman's rank correlation
coefficients were evaluated for correlation between
serum sCD163 and the other clinical factors with con-
tinuous variables. The Mann–Whitney U test was per-
formed for two-group comparisons. One-way analysis of
variance was performed followed by post-hoc analysis
(Dunn's multiple comparisons test) for multi-group
comparisons. Overall survival time was defined as the
number of months from PM/DM-related ILD diagnosis
(the date of the first HRCT evaluation) until all-cause
death or at censoring. Patients were censored if alive on
30 June 2015. Cox proportional hazard modeling was
used to identify prognostic factors. To estimate the cut-
off value of serum sCD163 level, time-dependent re-
ceiver operating characteristic analysis was performed,
as described previously [25, 26]. The Kaplan–Meier sur-
vival method and the log-rank test were employed to
compare the survival rate between groups. Values of P <
0.05 were considered significant. Statistical analyses were
performed by using R software version 2.15.1 (The R
Foundation for Statistical Computing, Austria) and SPSS
software version 13.0 (SPSS, USA).
Results
Baseline characteristics
Baseline characteristics of patients with PM/DM-related
ILD are summarized in Table 1. The numbers of patients
diagnosed with classic DM, CADM, and PM were 24,
21, and 3, respectively. Twenty patients (42%) had a
smoking history. The median serum levels of CK and C-
reactive protein (CRP) were almost within normal limits.
Serum ferritin levels were highly variable, ranging from
14 ng/mL to 12,701 ng/mL. Using immunoprecipitation
methods, anti-melanoma differentiation-associated genes
5 (MDA5) antibody and anti-aminoacyl-tRNA synthe-
tase (ARS) antibody were detected in 14 patients (29%)
and 19 patients (40%), respectively. Mildly decreased
values of arterial partial pressure of oxygen (PaO2),
percent predicted FVC, and percent predicted DLco
were commonly observed. The BAL fluid revealed a
slightly high percentage of lymphocytes (median 7.2%,
range 1.2–70.0%). All patients received radiological ex-
aminations using chest HRCT, in which bilateral
consolidation and/or ground glass attenuation were
commonly shown.
Serum sCD163
Serum concentrations of sCD163 are compared in
Fig. 1a. The median value of serum sCD163 was 818 ng/
mL (range 300–2759 ng/mL) in patients with PM/DM-
related ILD, which was relatively higher than that in pa-
tients with PM/DM without ILD (median 716 ng/mL,
range 250–1101 ng/mL). Patients with PM/DM, regard-
less of the presence/absence of ILD, had significantly
higher sCD163 levels than healthy volunteers (median
340 ng/mL, range 127–647 ng/mL).
Table 1 shows the correlation between serum sCD163
levels and other clinical factors at PM/DM-related ILD
diagnosis. Although the coefficients were generally low,
serum sCD163 was positively correlated with serum CRP
(r = 0.322, P = 0.03) and negatively correlated with %
Table 1 Baseline characteristics and the correlations with serum
soluble CD163 levels in patients with polymyositis/dermatomyositis-
related interstitial lung disease
Variables Patients (n = 48) r P value
Age at the ILD diagnosis
(years)
55, 32–76 −0.05 0.72
Male 17 (35%) − −
Current or former smoker 20 (42%) − −
CADM/classic DM/PM 21 (44%)/24 (50%)/3 (6%) − −
Fever 20 (42%) − −
Cough 20 (42%) − −
Dyspnea 23 (48%) − −
Muscle pain or weakness 27 (56%) − −
Rash typical of DM 45 (94%) − −
Raynaud’s phenomenon 5 (10%) − −
Arthralgia 17 (35%) − −
CK (IU/mL) 162, 24–5274 0.24 0.10
CRP (mg/dL) 0.36, 0.03–8.33 0.32 0.03
KL-6 (U/mL) 883, 249–4323 0.14 0.33
Ferritin (ng/mL) 116.5, 14–12701 0.25 0.08






Predicted FVC (%) 65.8, 40.6–107.7 (n = 45) −0.30 0.045
Predicted DLco (%) 60.3, 27.4–127.2 (n = 18) −0.15 0.55
BAL-lymphocytes (%) 7.2, 1.2–70.0 (n = 35) 0.03 0.85
Data are presented as number (%) or median, range. All P values are derived
from the Spearman's rank correlation coefficient. ARS aminoacyl-tRNA synthe-
tase, BAL bronchoalveolar lavage, CADM clinically amyopathic dermatomyositis,
CK creatine kinase, CRP C-reactive protein, DLco diffusing capacity of the lung
for carbon monoxide, DM dermatomyositis, FVC forced vital capacity, ILD inter-
stitial lung disease, KL-6 Krebs von den Lungen-6, PaO2 arterial partial pressure
of oxygen, MDA5 melanoma differentiation-associated gene 5,
PM, polymyositis
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predicted FVC (r = −0.301, P = 0.045). There was weak,
non-significant correlation with serum ferritin (r =
0.25, P = 0.08). Patients with fever and arthralgia had
significantly higher sCD163 than those without such
symptoms (Table 2). The comparison of sCD163
levels according to the profile of myositis-specific
autoantibodies is shown in Fig. 1b. Although not sig-
nificant, patients with anti-MDA5 antibody exhibited
relatively higher values.
Clinical course
The median follow-up period in patients with PM/DM-re-
lated ILD was 85.2 months (range 5.8–211.4 months).
Only two patients were lost to follow up. Most patients
(46/48, 96%) received immunosuppressive therapy after
ILD diagnosis. Among these patients, combination regi-
mens of high-dose corticosteroids and immunosuppress-
sants, including cyclophosphamide, cyclosporine, and
tacrolimus, were administered to 38 patients; in contrast,
corticosteroid monotherapy was selected for the other 8
patients. Although most patients had a favorable response
to the treatment, 13 patients died during the follow-up
period. The most common cause of death was respiratory
failure due to ILD (n = 9), followed by cancer of unknown
primary origin (n = 1), myocarditis (n = 1), rupture of aor-
tic aneurysm (n = 1), and unknown cause (n = 1). Among
the non-surviving patients, lung specimens were available
in three patients, which showed diffuse alveolar damage
on surgical lung biopsy (n = 1) or autopsy (n = 1) and
usual interstitial pneumonia with moderate lymphocytic
alveolitis on surgical lung biopsy (n = 1).
The results of the univariate Cox proportional hazard
model are listed in Table 3. Among the baseline clinical
factors, presence of fever, higher level of serum ferritin,
higher level of serum sCD163, lower PaO2, and lower
percent predicted FVC were significantly associated with
worse prognosis. The age-adjusted and gender-adjusted
hazard ratio for serum sCD163 (per 100 ng/mL increase)
was 1.27 (95% confidence interval 1.11–1.45, P < 0.001).
Additionally, even when classifying the four patients
whose cause of death was not respiratory failure due to
ILD into censored cases, the prognostic significance of
serum sCD163 remained (age-adjusted and gender-
adjusted hazard ratio 1.26, 95% confidence interval
1.09–1.45, P = 0.002). As shown in Fig. 2a, the cutoff for
survival was calculated as 800 ng/mL. The comparisons
of baseline characteristics between patients with higher
and lower values of serum sCD163 are summarized in
Additional file 1: Table S2. The patients with higher
serum sCD163 had significantly lower survival rates than
those with lower serum sCD163 (log rank test, P =
0.043) (Fig. 2b).
Immunohistochemical findings
The immunohistochemical results for lung sections are
shown in Fig. 3. CD163 expression in resected lung sec-
tions from an early lung cancer patient (Fig. 3a–d), a
surviving patient with classic DM-related ILD (Fig. 3e–
h; 66 year-old male patient, serum sCD163 = 519 ng/
mL), and a non-surviving patient with classic DM-
related ILD (Fig. 3i–l; 32 year-old male patient, serum
sCD163 = 1572 ng/mL) were evaluated. Compared with
Fig. 1 Comparison of serum soluble CD163 levels. a Patients with polymyositis (PM)/dermatomyositis (DM)-related interstitial lung disease (ILD)
(n = 48) vs patients with PM/DM without ILD (n = 10) vs healthy volunteers (n = 20). b Patients with PM/DM-related ILD with anti-melanoma
differentiation-associated gene 5 (MDA5) antibody (n = 14) vs those with anti-aminoacyl-tRNA synthetase (ARS) antibody (n = 19) vs those
without both antibodies (n = 15). One-way analysis of variance followed by post-hoc analysis (Dunn's multiple comparisons test) was used for
multi-group comparisons
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normal lung, accumulation of CD163-positive macro-
phages at alveolar spaces was more evident in the lungs
of the two patients with classic DM-related ILD. Espe-
cially, the macrophage infiltration in the non-survivor’s
lung was apparently severe, mainly at alveolar spaces
and partly at alveolar walls.
Discussion
In this study, we evaluated the clinical significance of
sCD163 in patients with PM/DM-related ILD. Serum
sCD163 levels at ILD diagnosis were associated with
several clinical factors and even the prognosis, sug-
gesting that this molecule might be a potential bio-
marker of the disease.
The expression of CD163, a macrophage-specific
marker within the macrophage/monocyte lineage, is in-
tricately regulated by various factors, such as IL-6, IL-10,
interferon-γ, tumor necrosis factor (TNF)-α, and cortico-
steroids. Cleavage of CD163 from activated macro-
phages, which is performed by a disintegrin and
metalloproteinase 17/TNF-α converting enzyme in re-
sponse to several inflammatory mediators, leads to an
increase in sCD163 in the serum [10, 11]. In fact, the
serum sCD163 levels in our patients were correlated
with the presence of fever and serum CRP levels,
Table 2 Comparison between baseline categorical variables
and serum soluble CD163 levels in patients with polymyositis/
dermatomyositis-related interstitial lung disease
Variables Soluble CD163, ng/mL P value
Male/female 814 (300–1572)/822 (305–2759) 0.66
Current or former
smoker/never smoker
791 (300–2758)/834 (305–2512) 0.39
CADM/others 730 (305–1750)/862 (300–2759) 0.09
Fever, yes/no 1009 (428–2512)/742 (300–2759) 0.03
Cough, yes/no 806 (426–1572)/826 (300–2759) 0.59
Dyspnea, yes/no 814 (428–2759)/822 (300–1572) 0.48
Muscle pain or weakness,
yes/no
862 (300–2759)/730 (305–1750) 0.09
Rash typical of DM, yes/no 789 (300–2759)/1124 (814–1213) 0.30
Raynaud’s phenomenon,
yes/no
593 (426–1137)/822 (300–2759) 0.27
Arthralgia, yes/no 1124 (305–2512)/773 (300–2759) 0.02
Anti-MDA5 antibody,
positive/negative
887 (495–2512)/778 (300–2759) 0.09
Data are presented as median (observed range). All P values are derived from
the Mann–Whitney U test. CADM clinically amyopathic dermatomyositis, DM
dermatomyositis, MDA5 Melanoma differentiation-associated gene 5
Table 3 Analysis of prognostic factors in patients with polymyositis/dermatomyositis-related interstitial lung disease using the Cox
proportional hazard model
Variables Unadjusted HR 95% CI P Age-adjusted and
gender-adjusted HR
95% CI P
Age (per 1 year increase) 1.01 0.96–1.07 0.62 − − −
Male 1.93 0.61–6.09 0.26 − − −
Current or former smoker 2.27 0.71–7.23 0.17 1.96 0.47–8.24 0.36
CADM 0.37 0.10–1.38 0.14 0.41 0.11–1.60 0.12
Fever 4.29 1.27–14.50 0.02 4.68 1.36–16.10 0.01
Cough 0.65 0.20–2.16 0.48 0.76 0.22–2.67 0.67
Dyspnea 2.30 0.69–7.64 0.18 2.65 0.78–9.03 0.12
Muscle pain or weakness 2.69 0.73–9.97 0.14 2.44 0.63–9.48 0.20
Rash typical for DM 0.40 0.09–1.85 0.24 0.47 0.10–2.27 0.35
Raynaud’s phenomenon 2.99 0.81–11.13 0.10 3.03 0.72–12.84 0.13
Arthralgia 1.54 0.49–4.90 0.46 1.39 0.42–4.59 0.59
CK (per 10 IU/mL increase) 1.00 0.995–1.01 0.97 1.00 0.994–1.006 0.96
CRP (per 1 mg/dL increase) 1.13 0.91–1.41 0.27 1.13 0.91–1.41 0.27
KL-6 (per 100 U/mL increase) 1.06 0.998–1.12 0.06 1.05 0.995–1.12 0.07
Ferritin (per 100 ng/mL increase) 1.02 1.01–1.04 0.01 1.03 1.01–1.05 0.01
Soluble CD163 (per 100 ng/mL increase) 1.22 1.09–1.36 0.001 1.27 1.11–1.45 <0.001
PaO2 on room air (per 10 Torr increase) 0.48 0.30–0.76 0.002 0.48 0.28–0.81 0.01
Anti-MDA5-positive 2.60 0.81–8.32 0.11 3.11 0.90–10.74 0.07
Percent predicted FVC (per 10% increase) 0.73 0.61–0.88 0.001 0.65 0.50–0.83 0.001
ARS aminoacyl-tRNA synthetase, CADM clinically amyopathic dermatomyositis, CI confidence interval, CK creatine kinase, CRP C-reactive protein, DM dermatomyo-
sitis, FVC forced vital capacity, HR hazard ratio, KL-6 Krebs von den Lungen-6, MDA5 melanoma differentiation-associated gene 5
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suggesting that elevated serum sCD163 is associated
with systemic inflammation. Notably, among macro-
phages, CD163 is mainly expressed on alternatively acti-
vated macrophages, rather than classically activated
macrophages [11]. Collectively, our results indicate the
significance of alternatively activated macrophages in the
inflammation seen in PM/DM-related ILD.
Serum sCD163 levels were significantly higher in pa-
tients with PM/DM-related ILD than those in healthy
volunteers, which is consistent with the results of the re-
cent study by Peng et al. [13]. They measured serum
sCD163 levels in 108 patients with PM/DM, consisted of
65 patients without ILD and 43 patients with ILD, and
found that serum sCD163 levels were correlated with
the activity of myositis. However, the clinical implication
of sCD163 in PM/DM-related ILD remains unclear. In
the present study, we focused on the ILD and further
advanced the understandings of sCD163 physiology in
this disease entity, particularly the relevance to pulmon-
ary function and prognosis.
In the Cox proportional hazard modeling, higher
serum sCD163 was significantly associated with worse
prognosis. This result implies that macrophage activa-
tion in PM/DM-related ILD plays an important role in
advancing the disease. In contrast, several studies have
evaluated the clinical significance of serum ferritin,
which is a key biomarker of MAS, in PM/DM-related
ILD [27–29]. Indeed, PM/DM is known to cause MAS,
in which the lack of T cell regulation and excessive pro-
duction of cytokines, including TNF-α, IL-1β, IL-6, and
IL-18, results in macrophage activation. Those previous
studies reported that hyperferritinemia was associated
with high mortality in patients with PM/DM-related
(particularly CADM-related) ILD, which was reproduced
in our cohort. Interestingly, there was a weak, but not
significant correlation between serum sCD163 levels and
ferritin levels in the present study. The total value of
serum ferritin might be affected by the storage of iron
(in the form of L-subunit ferritin). Meanwhile, sCD163
is secreted from activated macrophages and elevated for
days in peripheral blood, suggesting that this molecule
specifically reflects the degree of macrophage activation.
Although the superiority of either of the two biomarkers
could not be evaluated in our small cohort, our results
suggest that serum sCD163 may have value in the as-
sessment of disease severity in PM/DM-related ILD.
Human CD163 expression has been confirmed in sev-
eral tissues, such as red pulp macrophages, bone marrow
Fig. 2 Prognostic analysis. a Estimation of the cutoff for serum soluble CD163. b Survival curves in patients with polymyositis/dermatomyositis-
related interstitial lung disease. The cutoff for serum soluble CD163 is set at 800 ng/mL by comparing the integrated area under the curve (iAUC)
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macrophages, liver macrophages (Kupffer cells), and al-
veolar macrophages [10, 11]. In fact, on the basis of im-
munohistochemical analysis, one of the sources of
elevated serum sCD163 seemed to be the diseased lungs.
Additionally, more severe infiltration of CD163-positive
macrophages was found in the lung of the non-surviving
patient with DM-related ILD, compared with that in the
lung of the survivor (Fig. 3). Although we are speculat-
ing on the assessment of only two lung specimens, the
amount of infiltrating CD163-positive macrophage may
reflect the severity of PM/DM-related ILD. The follow-
ing results may support this: serum sCD163 was nega-
tively correlated with percent predicted FVC. Previous
studies demonstrate that alveolar macrophages produce
several profibrotic cytokines including transforming
growth factor-β, platelet-derived growth factor, and
fibroblast growth factor-2 [16, 30, 31]. Intriguingly,
Gibbons et al. recently demonstrated the paradoxical
and essential role played by macrophages in the patho-
genesis of lung fibrosis, in which activated macrophages
had both profibrotic and resolution-promoting roles
during fibrogenesis and the reversible phase, respectively
[17]. Thus, the exact functions of CD163-positive
macrophages in the pathogenesis of PM/DM-related
ILD remain unclear, but the infiltration to the lungs
may have some impact not only on inflammation but
also on fibrosis.
The present study has several limitations. First, this
was a small, retrospective study, which may have in-
volved various biases. Validation in larger and prospect-
ive cohorts is needed to confirm our preliminary results.
Second, there are several subtypes in the development of
PM/DM-related ILD, such as ILD-preceding, concomi-
tant, and myositis-preceding patterns, which indicates
the difficulty in determining the exact ILD onset, par-
ticularly in patients with no symptoms or only minor
symptoms. Our definition of ILD onset might be not ac-
curate in some patients. Third, the patients included in
the present study were not treated according to a con-
sistent regimen. Although most of the patients were
treated with corticosteroids and additional immunosup-
pressants, regimen variations, such as the doses and se-
lection of drugs, may have affected the clinical disease
course and prognosis. Additionally, we could not follow
serum sCD163 levels chronologically. It is unclear how
changes correlated with the clinical course of PM/DM-
Fig. 3 Immunohistochemical staining. Lung sections from an early lung cancer patient (a–d), a surviving patient with classic dermatomyositis
(DM)-related interstitial lung disease (ILD) (e–h: 66 year-old male patient, serum sCD163 = 519 ng/mL), and a non-surviving patient with classic
DM-related ILD (i–l: 32 year-old male patient, serum sCD163 = 1572 ng/mL) are shown. CD163-positive macrophages are evident in the lungs of
the two patients with classic DM-related ILD, especially in lung of the non-survivor. Accumulations of CD163-positive alveolar macrophages are
observed (arrows). a, e, and i Hematoxylin − eosin staining; scale bar 200 μm. b, f, and j Isotype controls, scale bar 200 μm. c, g, and k Staining
with anti-CD163 antibody with lower magnification (×40), scale bar 200 μm. d, h, and l Staining with anti-CD163 antibody with higher magnifica-
tion (×100), scale bar 100 μm
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related ILD. In future studies, clinical factors important
in the management of ILD, such as changes in pulmon-
ary function and oxygenation, and treatment response,
should be compared with changes in sCD163 levels.
These would explore the usefulness of this biomarker.
Conclusions
Serum sCD163 might have potential for predicting the
disease severity and prognosis in PM/DM-related ILD.
Our results suggest the involvement of macrophage acti-
vation in this disease.
Additional file
Additional file 1: Table S1. Baseline characteristics of all subjects
included in this study. Table S2. Comparison of baseline characteristics
between patients with higher and lower values of serum soluble CD163
(cutoff 800 ng/mL). (DOCX 45 kb)
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